The first domestic four-valent influenza vaccine was approved for marketing, and the forecast price is 80~120 yuan.
Yesterday (June 11), the State Drug Administration issued a notice stating that Hualan Biological Vaccine Co., Ltd. and Changchun Changsheng Biotechnology Co., Ltd. have separately approved the registration application for the production of tetravalent influenza virus split vaccine for prevention. Infection of influenza virus in people aged one year and older. This is China's first listed four-valent influenza vaccine. Before the influenza vaccine on the Chinese market was a trivalent influenza vaccine, the State Food and Drug Administration said that the listing of the tetravalent influenza virus split vaccine is a powerful force for China's influenza virus vaccine varieties. In addition, it will work with the trivalent flu vaccine to play an important role in my defense of the seasonal flu epidemic. It is understood that the approved tetravalent influenza virus lysing vaccine contains the influenza A virus in addition to the A1, A3 and BV viruses containing the common trivalent influenza vaccine. This is also the influenza season in China from 2017 to 2018. The main strain of the virus. The vaccine is prepared by adopting a virus strain recommended by the World Health Organization, harvesting the virus through chicken embryo hatching culture, and combining the inactivated vaccine production process. At the same time, in order to comprehensively evaluate the safety and effectiveness of the vaccine, the relevant units of the State Drug Administration have fully used domestic and foreign innovative drug research and development and evaluation through full follow-up, open review, forward-looking guidance, and program linkage. On the basis of experience, strict checks ensure that the registration work is scientific, objective and efficient. Influenza (abbreviated as flu) is mainly caused by influenza A (A) and B (B) viruses. Because of the frequent antigenic variation of the virus, it is highly contagious and spreads rapidly, and it is prone to widespread epidemics. Especially for infants, the elderly and patients with cardiopulmonary diseases, the infection with influenza virus may be accompanied by serious complications such as pneumonia, leading to severe illness or death. At present, flu vaccination is the most effective measure to prevent influenza diseases and outbreaks. The World Health Organization annually predicts influenza epidemic trends based on the global influenza epidemic, and recommends strains suitable for this year's flu vaccine production. Zhong Nanshan, an academician of the Chinese Academy of Engineering and a famous respiratory disease expert, said in an interview in January this year that the dominant strain popular in China at the end of last year and the beginning of this year is mainly type B. The performance characteristics of this virus are easy to be infected and the duration of the disease is long. Immunization is the most effective way to prevent influenza. According to the latest monitoring data of the National Health and Health Commission, the recent slow-release influenza reported cases are higher than the same period of the past three years, and the market demand for tetravalent influenza vaccine is expected to increase in the future. According to the data, Hualan Bio has an annual production capacity of 30 million copies of the tetravalent influenza virus split vaccine; Changsheng Bio has 10 million copies of the influenza vaccine production capacity. In addition, according to the CDE review data, there are currently 17 companies in the domestic research and development of tetravalent influenza vaccines, of which 14 have obtained clinical approvals. For the price issue that everyone cares about, China's Hong Kong region has already introduced and listed a four-valent influenza vaccine. The quotation indicates that the price of this vaccine is more than 300 Hong Kong dollars / needle to 350 Hong Kong dollars / needle, equivalent to 244 to 285 yuan. At present, some brokerages predict that the domestic four-price influenza vaccine will have a considerable price advantage over the products in Hong Kong, and the price is expected to be 80-120 yuan. Shandong Longze Mechanical Equipment Co.,Ltd , https://www.pelletmachinefactory.com